PRESS RELEASE: Dr. Patricia Deverka Appointed as IVI’s First Chief Science Officer

IVI is thrilled to announce Pat Deverka, MD has joined our organization as our first Chief Science Officer. Dr. Deverka. Dr. Deverka brings to IVI more than three decades of experience in health economic research, public policy, patient engagement and program measurement across several academic, corporate and non-profit institutions. Read the full press release [...]

2020-02-03T12:45:09-06:00February 4th, 2020|IVI News, Press|

What’s in Store for 2020?

Jennifer Bright discusses the following three trends that began in 2019 and will pick up steam this year: Increased demand for value information for drugs; Increased number of voices asking whether value assessment is done the right way; and Momentum to improve value assessment models. Read the full article here. Please note that a Scrip [...]

2020-02-26T16:39:47-06:00January 9th, 2020|IVI News, Viewpoints|

IVI Unveils Updates to Rheumatoid Arthritis Model

The Center for Biosimilars writes about IVI's recent updates to their IVI-RA value model to include biosimilars, triple therapy, Janus kinase (JAK) inhibitors, sarilumab, as well as updated treatment effect estimates based on additional randomized control trial (RCT) evidence, and updated cost estimates. Read the full article here.

2020-02-26T16:42:58-06:00January 8th, 2020|IVI News|

PRESS RELEASE: IVI’s Updated RA Model Examines New Treatment Options, Treatment Effects and Cost Estimates

IVI has just released the latest update to the organization's Rheumatoid Arthritis (RA) Value Assessment Model. The updated model now incorporates additional treatment options (triple therapy, Janus Kinase (JAK) inhibitors, sarilumab, and biosimilars), updated treatment effect estimates based on additional randomized controlled trial (RCT) evidence, and updated cost estimates. The model is also designed to [...]

2020-01-07T00:30:08-06:00January 7th, 2020|IVI News, Press|

PRESS RELEASE: IVI Research Brief Discusses Limitations of ICER’s Analysis for JAK Inhibitors

As part of its Value Blueprints series, IVI’s latest research brief grapples with a question prompted by ICER’s recent assessment of RA therapies: Do conventional value assessments address the questions most relevant to real-world decisions about treatment pathways for chronic diseases? In the brief, the authors discuss how the failure of ICER’s analysis to evaluate [...]

2019-12-10T13:20:31-06:00December 10th, 2019|IVI News, Press|

IVI Showcases OSVP at HealthEconomics.com’s “Big Ideas Accelerating Change” Challenge

As one of the nine finalists in HealthEconomics.com's inaugural challenge competition to accelerate change in health economics and outcomes research, IVI's Mark Linthicum offered a compelling case for how IVI's Open-Source Value Platform (OSVP) is catalyzing innovation to shake up value assessment. Mark's presentation, "Using Open-Source Models to Improve Value Assessment in the U.S.", outlined [...]

2019-12-05T15:26:31-06:00December 5th, 2019|IVI News|

IVI Submits Comments on ICER Draft Evidence Report on JAK Inhibitors for RA

IVI offered comments on ICER's recently released Draft Evidence Report examining the cost-effectiveness of Janus Kinase (JAK) Inhibitors for Rheumatoid Arthritis. In addition to commenting on the needs for transparency and the impacts of modeling assumptions on results, IVI's comments raise a broader question about the relevance of the analysis to decision making. IVI writes [...]

2019-11-13T13:07:31-06:00November 13th, 2019|IVI News, Viewpoints|

Jennifer Bright Explains How IVI Economic Models Improve Process of Value Assessment

At the National Health Council's event, Back to School: Patient Community Training on Value Assessment, IVI executive director Jennifer Bright explains the non-profit organization's mission to make value assessment more relevant to real decision making, how and why patient perspectives must be built into the front end of economic modeling, and how patients and patient [...]

2019-11-08T14:06:41-06:00November 8th, 2019|Events, IVI News|
Go to Top